ehealth digital library

Digital library of
the Tanzania
health
community

Effect of Single Nucleotide Polymorphisms in Cytochrome P450 Isoenzyme and N-acetyltransferase 2 Genes on the Metabolism of Artemisinin-Based Combination Therapies in Malaria Patients from Cambodia and Tanzania.

Staehli Hodel, E. M., Csajka, C., Ariey, F., Guidi, M., Kabanywanyi, A. M., Duong, S., Decosterd, L. A., Olliaro, P., Beck, H.-P. and Genton, B. (2013) Effect of Single Nucleotide Polymorphisms in Cytochrome P450 Isoenzyme and N-acetyltransferase 2 Genes on the Metabolism of Artemisinin-Based Combination Therapies in Malaria Patients from Cambodia and Tanzania. Antimicrobial agents and chemotherapy, 57 (2). pp. 950-8. ISSN 1098-6596

[img]
Preview
PDF
Eva_Maria_Staehli_Hodel.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (154kB)

Abstract

The pharmacogenetics of antimalarial agents are poorly known, although the application of pharmacogenetics might be critical in optimizing treatment. This population pharmacokinetic-pharmacogenetic study aimed at assessing the effects of single nucleotide polymorphisms (SNPs) in cytochrome P450 isoenzyme genes (CYP, namely, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5) and the N-acetyltransferase 2 gene (NAT2) on the pharmacokinetics of artemisinin-based combination therapies in 150 Tanzanian patients treated with artemether-lumefantrine, 64 Cambodian patients treated with artesunate-mefloquine, and 61 Cambodian patients treated with dihydroartemisinin-piperaquine. The frequency of SNPs varied with the enzyme and the population. Higher frequencies of mutant alleles were found in Cambodians than Tanzanians for CYP2C9*3, CYP2D6*10 (100C → T), CYP3A5*3, NAT2*6, and NAT2*7. In contrast, higher frequencies of mutant alleles were found in Tanzanians for CYP2D6*17 (1023C → T and 2850C → T), CYP3A4*1B, NAT2*5, and NAT2*14. For 8 SNPs, no significant differences in frequencies were observed. In the genetic-based population pharmacokinetic analyses, none of the SNPs improved model fit. This suggests that pharmacogenetic data need not be included in appropriate first-line treatments with the current artemisinin derivatives and quinolines for uncomplicated malaria in specific populations. However, it cannot be ruled out that our results represent isolated findings, and therefore more studies in different populations, ideally with the same artemisinin-based combination therapies, are needed to evaluate the influence of pharmacogenetic factors on the clearance of antimalarials.

Item Type: Article
Keywords: Nucleotide Polymorphisms, Cytochrome P450 Isoenzyme Genes, Malaria, Artemisinin-Based Combination Therapies, Cambodia and Tanzania
Subjects: Malaria > Diagnosis & treatment
Divisions: Other
Depositing User: Mr Joseph Madata
Date Deposited: 25 May 2015 06:00
Last Modified: 25 May 2015 06:00
URI: http://ihi.eprints.org/id/eprint/2109

Actions (login required)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics